Status:
TERMINATED
Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome
Lead Sponsor:
Duke University
Collaborating Sponsors:
GBS-CIDP foundation
Conditions:
Guillain-Barre Syndrome
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine if peripheral nerve ultrasound can be used as a supplemental tool to diagnose Guillain-Barre syndrome (GBS) in the acute setting and aid in prognostication.
Eligibility Criteria
Inclusion
- For GBS group: Inpatients with acute, progressive weakness and no alternative diagnosis, with onset less than 30 days prior to examination.
- For control group: Hospitalized patients on the inpatient neurology service who are being treated for non-peripheral nerve disorders (e.g. epilepsy, multiple sclerosis, or stroke).
- For all subjects: 18+ years of age
Exclusion
- \- Patients with any history of multifocal motor neuropathy (MMN), prior Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), or hereditary neuropathy (e.g. Charcot-Marie-Tooth)
Key Trial Info
Start Date :
September 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 5 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04053452
Start Date
September 30 2019
End Date
February 5 2024
Last Update
May 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Hospital
Durham, North Carolina, United States, 27710